Literature DB >> 2850215

A tumor necrosis factor binding protein is present in human biological fluids.

C Peetre1, H Thysell, A Grubb, I Olsson.   

Abstract

Tumor necrosis factor (TNF) possesses both beneficial and toxic bioactivities. Mechanisms may operate to counteract harmful effects. We have identified a TNF binding protein (TNF-BP), which shows increased levels in serum and urine of patients on regular hemodialysis treatment (RDT). TNF-BP inhibited the specific binding of human recombinant TNF (rTNF) to its cell surface receptor. Results from gel chromatography demonstrated the presence in serum and urine of a macromolecule with an apparent molecular weight of 50,000, which formed a complex with rTNF. A 62-fold purification of TNF-BP from urine of patients on RDT was achieved by ion exchange chromatography and gel chromatography. Partially purified TNF-BP reduced the growth inhibitory effect of rTNF on a susceptible leukemia cell line. TNF-BP may act as a regulator of the biological activity of TNF and could have beneficial effects in certain inflammatory conditions.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2850215     DOI: 10.1111/j.1600-0609.1988.tb00220.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  21 in total

Review 1.  Cytokines, receptors, and inhibitors.

Authors:  G Gehr; T Braun; W Lesslauer
Journal:  Clin Investig       Date:  1992-01

2.  Inhibition of the release of soluble tumor necrosis factor receptors in experimental endotoxemia by an anti-tumor necrosis factor-alpha antibody.

Authors:  J Jansen; T van der Poll; M Levi; H ten Cate; H Gallati; J W ten Cate; S J van Deventer
Journal:  J Clin Immunol       Date:  1995-01       Impact factor: 8.317

3.  Bone mineral density and bone turnover in non-cirrhotic patients with chronic hepatitis C and sustained virological response to antiviral therapy with peginterferon-alfa and ribavirin.

Authors:  E Redondo-Cerezo; F Casado-Caballero; J L Martin-Rodriguez; J Hernandez-Quero; F Escobar-Jimenez; J L Gonzalez-Calvin
Journal:  Osteoporos Int       Date:  2014-03-28       Impact factor: 4.507

4.  Maternal death following cardiopulmonary collapse after delivery: amniotic fluid embolism or septic shock due to intrauterine infection?

Authors:  Roberto Romero; Nicholas Kadar; Edi Vaisbuch; Sonia S Hassan
Journal:  Am J Reprod Immunol       Date:  2010-03-15       Impact factor: 3.886

5.  Tumor necrosis factor (TNF)-dependent shedding of the p55 TNF receptor in a baboon model of bacteremia.

Authors:  H Redl; G Schlag; G R Adolf; B Natmessnig; J Davies
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

Review 6.  Tumor necrosis factor receptors--structure and function.

Authors:  J Rothe; G Gehr; H Loetscher; W Lesslauer
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

7.  On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin.

Authors:  M Lantz; H Thysell; E Nilsson; I Olsson
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

8.  Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia.

Authors:  G A Spinas; U Keller; M Brockhaus
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

9.  Adenovirus E3 14.7K protein functions in the absence of other adenovirus proteins to protect transfected cells from tumor necrosis factor cytolysis.

Authors:  T M Horton; T S Ranheim; L Aquino; D I Kusher; S K Saha; C F Ware; W S Wold; L R Gooding
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

10.  Inhibition of tumour necrosis factor alpha (TNF-alpha)-induced neutrophil respiratory burst by a TNF inhibitor.

Authors:  A Ferrante; B Hauptmann; P Seckinger; J M Dayer
Journal:  Immunology       Date:  1991-03       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.